Login
$ODTX
$19.39 +$0.25 (1.31%) Live

$ODTX SEC Filings

Filed On Filing
05 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis

20 Oct 2026 8-K: Regulation FD Disclosure

Forward-looking statements and third-party information This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other...

09 Sep 2026 8-K: Regulation FD Disclosure

Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, In...

06 Aug 2026 10-Q
04 Aug 2026 8-K: Results of Operations and Financial Condition

Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October

23 Jun 2026 8-K: Regulation FD Disclosure

Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, In...

17 Jun 2026 10-Q
17 Jun 2026 8-K: Results of Operations and Financial Condition

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis

05 Jun 2026 SCHEDULE 13G
18 May 2026 SCHEDULE 13G
18 May 2026 SCHEDULE 13D
18 May 2026 SCHEDULE 13D
15 May 2026 SCHEDULE 13D
15 May 2026 SCHEDULE 13D
13 May 2026 Form 4: Tpg Gp A, Llc, Former 10% Owner and 2 others

Acquired 423,111 shares (Other Transaction) · Disposed of 2,351 shares (Other Transaction) ($42.3K) · Received 1,880,497 shares by conversion · 2 more

12 May 2026 Form 4: Dimension Capital II, L.p., Director

Received 1,709,543 shares by conversion · Bought 1,111,111 shares ($20M)

12 May 2026 Form 3: Dimension Capital II, L.p., Director

Holds 512,862 shares of Common Stock

11 May 2026 Form 4: Sr One Capital MANAGEMENT, Llc, 10% owner and 1 other

Received 2,921,061 shares by conversion · Received 320,047 shares by exercise · Sold 1,780 shares ($32K) · 1 more

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support